Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
92.57
+1.48 (1.62%)
At close: Dec 20, 2024, 4:00 PM
92.15
-0.42 (-0.45%)
After-hours: Dec 20, 2024, 6:57 PM EST
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.55B in the quarter ending September 30, 2024, with 7.02% growth. This brings the company's revenue in the last twelve months to $28.30B, up 3.31% year-over-year. In the year 2023, Gilead Sciences had annual revenue of $27.12B, down -0.60%.
Revenue (ttm)
$28.30B
Revenue Growth
+3.31%
P/S Ratio
4.08
Revenue / Employee
$1,572,167
Employees
18,000
Market Cap
115.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Cigna Group | 229.75B |
Elevance Health | 174.02B |
Sanofi | 54.03B |
Bristol-Myers Squibb Company | 47.44B |
Medtronic | 33.00B |
Amgen | 32.53B |
Stryker | 21.97B |
Boston Scientific | 15.91B |
GILD News
- 1 day ago - Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
- 3 days ago - Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure - Seeking Alpha
- 4 days ago - U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire
- 4 days ago - Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - Business Wire
- 8 days ago - Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis - Business Wire
- 9 days ago - Gilead appoints Sanofi official Dietmar Berger as next chief medical officer - Reuters
- 9 days ago - Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Business Wire
- 12 days ago - Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 - Business Wire